Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as Intraepithelial lymphocytes

被引:72
作者
Kobayashi, Taku
Okamoto, Susumu
Iwakami, Yuko
Nakazawa, Atsushi
Hisamatsu, Tadakazu
Chinen, Hiroshi
Kamada, Nobuhiko
Imai, Toshio
Goto, Hidemi
Hibi, Toshifumi
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, Tokyo 1608582, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi, Japan
[3] Kan Res Inst, Kyoto, Japan
关键词
inflammatory bowel disease; fractalkine; CX3CR1; CD4; CD28; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; CHEMOKINE FRACTALKINE; RECEPTOR EXPRESSION; PERIPHERAL-BLOOD; IN-VIVO; CX3CL1; PHENOTYPE; MIGRATION; CX(3)CR1;
D O I
10.1002/ibd.20113
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: CX3CL1/Fractalkine (FKN) has been reported to play important roles in various inflammatory diseases. We examined the role of FKN and its receptor CX3CR1 in T-cell migration in the inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD). Methods: CX3CR1 expression on peripheral CD4(+) cells from normal controls (NL n = 24) and IBD patients (UC n = 28, CD n = 26) was examined using flow cytometry. CX3CR1(+) CD4(+) T cells were further characterized for surface antigens, cytokine production, and cytotoxic granule release by flow cytometry and ELISA. FKN expression in 53 colonic biopsy specimens (UC n = 20, CD n = 23, NL n = 10) was analyzed by quantitative PCR and immunohistochemistry. Isolated lamina propria and intraepithelial lymphocytes were also analyzed by flow cytometry (UC n = 10, CD n = 10, NL n = 6). Results: CX3CR1(+) CD4(+) cells were increased in IBD while they were virtually absent in controls. Upregulation of CX3CR1 on CD4+ T cells was positively correlated with disease activity. These unique T cells expressed markers for both effector memory and cytotoxic cells. Interestingly, CX3CR1 was expressed on CD4+ T cells lacking CD28. CX3CR1(+)CD28(-)CD4(+) cells produced more IFN-gamma and TNF-alpha than CX3CR1(-) counterparts and released cytotoxic granules. FKN mRNA was upregulated in inflamed colonic tissues and robust expression of FKN was immumohistochemically observed on epithelial cells. Although CX3CR1(+) CD4(+) cells could not be detected in the gut, CD28(-)CD4(+) cells were found in IBD mainly as intraepithelial lymphocytes. Conclusions: FKN/CX3CR1 may contribute to the pathogenesis of IBD through the emergence of unique CX3CR1(+)CD28(-)CD4(+) T cells that can act both as proinflammatory and cytotoxic cells.
引用
收藏
页码:837 / 846
页数:10
相关论文
共 37 条
[1]   Fractalkine preferentially mediates arrest and migration of CD16+ monocytes [J].
Ancuta, P ;
Rao, R ;
Moses, A ;
Mehle, A ;
Shaw, SK ;
Luscinskas, FW ;
Gabuzda, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (12) :1701-1707
[2]   A new class of membrane-bound chemokine with a CX(3)C motif [J].
Bazan, JF ;
Bacon, KB ;
Hardiman, G ;
Wang, W ;
Soo, K ;
Rossi, D ;
Greaves, DR ;
Zlotnik, A ;
Schall, TJ .
NATURE, 1997, 385 (6617) :640-644
[3]  
Blaschke S, 2003, J RHEUMATOL, V30, P1918
[4]   Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype [J].
Brand, S ;
Hofbauer, K ;
Dambacher, J ;
Schnitzler, F ;
Staudinger, T ;
Pfennig, S ;
Seiderer, J ;
Tillack, C ;
Konrad, A ;
Göke, B ;
Ochsenkühn, T ;
Lohse, P .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (01) :99-106
[5]   MONOCYTE CHEMOATTRACTANT PROTEIN-1 ACTS AS A T-LYMPHOCYTE CHEMOATTRACTANT [J].
CARR, MW ;
ROTH, SJ ;
LUTHER, E ;
ROSE, SS ;
SPRINGER, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3652-3656
[6]   CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease [J].
Connor, SJ ;
Paraskevopoulos, N ;
Newman, R ;
Cuan, N ;
Hampartzoumian, T ;
Lloyd, AR ;
Grimm, MC .
GUT, 2004, 53 (09) :1287-1294
[7]   Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy [J].
Damås, JK ;
Boullier, A ;
Wæhre, T ;
Smith, C ;
Sandberg, WJ ;
Green, S ;
Aukrust, P ;
Quehenberger, O .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (12) :2567-2572
[8]  
Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9
[9]  
Foussat A, 2000, EUR J IMMUNOL, V30, P87, DOI 10.1002/1521-4141(200001)30:1<87::AID-IMMU87>3.0.CO
[10]  
2-7